Abstract
Osteoporosis was related with depression especially in patients treated with psychotropic medicine. Selective serotonin reuptake inhibitors (SSRIs), the first-line treatment of depression, could up-regulate the extracellular serotonin (5-HT) levels and affect the serotonin system in bone metabolism. 5-HT transporter(5-HTT) knockout results in bone mass decreased, architecture altered and mechanical properties impaired. Antidepressant-induced osteoporosis has direct and dose-dependent effects. Thus depression patients should evaluate skeletal system and receive antiosteoporotic treatments regularly, particularly during use of SSRI. But some reports have shown a dissociation of Major depressive disorder (MDD) and bone mineral density (BMD). The relationship between depression, BMD and bone metabolism remains elusive. Further studies will be tackled by ‘OMICS’ to understand possible mechanisms and develop new antidepressant for MDD.
Keywords: Bone mineral density, depression, OMICS, osteoporosis, SSRIs.
Current Signal Transduction Therapy
Title:Insight into the Physiopathologic Mechanism for the Coexistence of Depression and Osteoporosis
Volume: 10 Issue: 1
Author(s): Ying Wu, Yi Yang, Haishan Wu, Beibei Zhang, Hui Tang, Jingping Zhao and Jindong Chen
Affiliation:
Keywords: Bone mineral density, depression, OMICS, osteoporosis, SSRIs.
Abstract: Osteoporosis was related with depression especially in patients treated with psychotropic medicine. Selective serotonin reuptake inhibitors (SSRIs), the first-line treatment of depression, could up-regulate the extracellular serotonin (5-HT) levels and affect the serotonin system in bone metabolism. 5-HT transporter(5-HTT) knockout results in bone mass decreased, architecture altered and mechanical properties impaired. Antidepressant-induced osteoporosis has direct and dose-dependent effects. Thus depression patients should evaluate skeletal system and receive antiosteoporotic treatments regularly, particularly during use of SSRI. But some reports have shown a dissociation of Major depressive disorder (MDD) and bone mineral density (BMD). The relationship between depression, BMD and bone metabolism remains elusive. Further studies will be tackled by ‘OMICS’ to understand possible mechanisms and develop new antidepressant for MDD.
Export Options
About this article
Cite this article as:
Wu Ying, Yang Yi, Wu Haishan, Zhang Beibei, Tang Hui, Zhao Jingping and Chen Jindong, Insight into the Physiopathologic Mechanism for the Coexistence of Depression and Osteoporosis, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1574362410666150311000100
DOI https://dx.doi.org/10.2174/1574362410666150311000100 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oestradiol Signalling in the Hippocampus
Current Neuropharmacology Changes in Serum Amino Acids in Migraine Patients without and with Aura and their Possible Usefulness in the Study of Migraine Pathogenesis
CNS & Neurological Disorders - Drug Targets The Innate Immune System and Fever under Redox Control: A Narrative Review
Current Medicinal Chemistry Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Adipokines and Adipocyte Targets in the Future Management of Obesity and the Metabolic Syndrome
Mini-Reviews in Medicinal Chemistry GABAergic Contributions to the Pathophysiology of Depression and the Mechanism of Antidepressant Action
CNS & Neurological Disorders - Drug Targets Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Medical Treatment of Hirsutism in Women
Current Medicinal Chemistry Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update
CNS & Neurological Disorders - Drug Targets Emerging Targets for the Pharmacological Treatment of Depression: Focus on Melatonergic System
Current Medicinal Chemistry Antigonadotropins: A Novel Strategy to Halt Alzheimers Disease Progression
Current Pharmaceutical Design Re-Discovering PDE3 Inhibitors - New Opportunities for a Long Neglected Target
Current Topics in Medicinal Chemistry Chronic Stress and Alzheimers Disease-Like Pathogenesis in a Rat Model: Prevention by Nicotine
Current Neuropharmacology Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Circulating Aminopeptidase Activities in Men and Women with Essential Hypertension
Current Medicinal Chemistry On the Role of Neuropeptides in the Hypothalamic Regulation of Food Intake
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A New Target for Diagnosis and Treatment of CNS Disorders: Agmatinergic System
Current Medicinal Chemistry Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design Polycystic Ovary Syndrome: A Contemporary Clinical Approach
Current Pharmaceutical Design